Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
topiramate + flunarizine
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Topiramate + flunarizine is a fixed-dose combination of two small molecule drugs used primarily for migraine prophylaxis. Topiramate is an anticonvulsant that acts by blocking voltage-dependent sodium channels, enhancing GABA-A receptor activity, inhibiting AMPA/kainate glutamate receptors, and weakly inhibiting carbonic anhydrase. Flunarizine is a selective calcium channel blocker with calmodulin binding properties and histamine H1 antagonism; it also exhibits antidopaminergic effects. The combination has demonstrated efficacy and good tolerability in reducing the frequency and severity of migraines compared to either agent alone[1][2][5]. Topiramate may mitigate the weight gain commonly associated with flunarizine[1][2].
- Other names
- topiramate + flunarizine
02
Targets
iGluR (Ionotropic receptor 76b (Ir76b))CA2 (Carbonic Anhydrase 2)DRD2 (Dopamine D2 Receptor)GABRR (GABA-A receptor subunit rho)VDCC (L-type voltage-dependent calcium channel (often specified further as subunits such as CaV1.2 in humans))HRH1 (Histamine H1 Receptor)NaV (Voltage-gated sodium channels)CA (Carbonic anhydrase)
Beyond the preview
Go deeper on topiramate + flunarizine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on topiramate + flunarizine.